Every 8-K that Contineum Therapeutics, Inc. (CTNM) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CTNM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CTNM filings page.
Contineum Therapeutics, Inc. (CTNM) reported that its Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 in major depressive disorder did not meet its primary efficacy endpoint. The study evaluated improvement from baseline in Montgomery-Åsberg Depression Rating Scale total score at Day 5 versus placebo. JNJ-5120/PIPE-307 was reported to be well tolerated with no new safety signals. Johnson & Johnson, which is developing the drug under a global license and development agreement with Contineum, is continuing to analyze the Phase 2 data, including prespecified exploratory endpoints, to assess the clinical relevance of the findings and determine potential next steps.
Contineum Therapeutics reported second-quarter 2026 results and progress across its pipeline of oral small-molecule drugs for inflammatory and fibrotic diseases. The company is dosing patients in PROPEL-IPF, a 26-week global Phase 2 trial of PIPE-791 in approximately 324 idiopathic pulmonary fibrosis patients, with over 55 sites active in eight countries. Johnson & Johnson completed enrollment of 107 adults in the Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 for major depressive disorder. PIPE-791 also produced positive topline safety and exploratory pain data in an exploratory Phase 1b chronic pain study.
Contineum streamlined discovery efforts and implemented a limited workforce reduction, including the departure of Chief Scientific Officer Daniel Lorrain, to focus resources on its highest-potential programs. Cash, cash equivalents and marketable securities were $236.6 million as of June 30, 2026, and the company believes this supports operations through mid-2029. In the quarter, research and development expenses were $12.7 million (down 10% year over year), general and administrative expenses were $4.7 million (up 23%), and net loss was $15.2 million compared with $16.0 million a year earlier.
Contineum Therapeutics, Inc. furnished an updated corporate overview describing its pipeline of small-molecule therapies targeting diseases with significant unmet need, led by PIPE-791, a brain-penetrant LPAR1 antagonist in development for idiopathic pulmonary fibrosis (IPF) and chronic pain.
The company highlights clinical validation of the LPAR1 target in IPF/PPF and describes PIPE-791 as a once-daily oral candidate with high and sustained receptor occupancy and favorable Phase 1 safety. A global Phase 2 IPF trial is underway with approximately 324 subjects and an estimated completion in June 2028. Early Phase 1B data in chronic pain show a favorable safety profile and numerically better pain outcomes versus placebo.
The overview also describes PIPE-307 (JNJ-5120), a selective M1R antagonist for major depressive disorder partnered with Janssen under a deal including $50 million upfront cash, a $25 million equity investment, and over $1 billion in potential milestones, with royalties from low-double digits to high-teens. Management states that existing cash and cash equivalents are projected to provide a cash runway through mid-2029.
Contineum Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 26, 2026. As of the record date of April 27, 2026, there were 32,723,877 shares of Class A common stock outstanding and entitled to vote.
Stockholders elected three Class II directors to serve until the 2029 annual meeting. Evert Schimmelpennink received 21,773,559 votes for and 131,384 withheld; Lori M. Lyons-Williams received 20,593,715 for and 1,311,228 withheld; and Diego Miralles, M.D. received 21,673,187 for and 231,756 withheld. Each proposal had 6,133,812 broker non-votes.
Stockholders also ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 28,021,047 votes for, 16,104 against and 1,604 withheld.
Contineum Therapeutics reported first-quarter 2026 results, highlighting clinical progress and a strengthened financial position. The company recently announced positive topline data from an exploratory Phase 1b trial of PIPE-791 for chronic osteoarthritis or low back pain, which met its safety and tolerability objective and showed numerically greater pain improvements versus placebo. It also began patient dosing in PROPEL-IPF, a 26-week global Phase 2 trial of PIPE-791 in idiopathic pulmonary fibrosis, and Johnson & Johnson is running the Phase 2 Moonlight-1 trial of PIPE-307/JNJ-89495120 in major depressive disorder.
Cash, cash equivalents and marketable securities totaled $246.3 million as of March 31, 2026, and the company expects its cash runway to extend through mid-2029. Research and development expenses were $11.6 million, a 15 percent decrease from the first quarter of 2025, while general and administrative expenses were $5.3 million, a 20 percent increase. Net loss was $14.5 million for the quarter, compared with $16.0 million a year earlier, or $0.39 per share based on 37,339,026 weighted-average shares outstanding.
Contineum Therapeutics reported positive topline data from an exploratory Phase 1b trial of PIPE-791, an oral, once-daily 10 mg LPA1 receptor antagonist, in chronic osteoarthritis pain (COAP) and chronic low back pain (CLBP). The randomized, double-blind, placebo-controlled, 4‑week crossover study enrolled 43 patients, split between COAP and CLBP.
The trial met its primary objective of assessing safety and tolerability, with no serious adverse events reported and most treatment-emergent events, such as headache and fatigue, described as mild to moderate. Vital signs, including blood pressure and orthostatic measures, showed no clinically meaningful changes.
Exploratory efficacy measures using the 11‑point Pain‑Intensity Numerical Rating Scale showed that patients receiving PIPE-791 generally had greater numerical improvements in average and worst daily pain than those on placebo, particularly in the COAP group. Additional exploratory endpoints, including the proportion of patients achieving at least a 30% pain reduction and a modified knee osteoarthritis function scale, were described as supporting the positive pain findings. Management stated that these results support further evaluation of PIPE-791 for chronic pain.
Contineum Therapeutics, Inc. reported a fourth-quarter 2025 net loss of $15.2 million, similar to the prior-year quarter, as it continued investing in its pipeline. For the full year 2025, net loss was $59.98 million.
Cash, cash equivalents and marketable securities totaled $262.9 million as of December 31, 2025, and the company believes this is sufficient to fund planned operations through mid-2029. Fourth-quarter research and development expenses were $12.8 million, a 2 percent decrease from 2024, while general and administrative expenses were $4.4 million, an 8 percent increase.
The company initiated patient dosing in PROPEL-IPF, a global Phase 2 trial of PIPE-791 in idiopathic pulmonary fibrosis, and expects topline data from an exploratory PIPE-791 Phase 1b chronic pain trial in the second quarter of 2026. Contineum also highlighted a Phase 2 trial of PIPE-307/JNJ-89495120 in major depressive disorder being conducted by Johnson & Johnson. Separately, it amended its at-the-market Sales Agreement with Leerink Partners, filing a new prospectus supplement for the offer and sale of up to $100,000,000 of Class A common stock, exclusive of amounts previously sold, and agreed not to sell shares under this facility through March 11, 2026.
Contineum Therapeutics, Inc. adopted a 2026 Employment Inducement Equity Incentive Plan, initially reserving 750,000 shares of its Class A common stock for awards.
The plan’s terms are described as substantially similar to the company’s 2024 Equity Incentive Plan, except that incentive stock options cannot be issued and awards may only be granted to recipients eligible under applicable Nasdaq rules. It was approved by the Board without stockholder approval under Nasdaq Listing Rule 5635(c)(4).
Awards may be granted only to new employees or rehires in connection with the commencement of employment when the grant is an inducement material to joining the company. Full plan documents and related stock option and restricted stock unit agreement forms will be filed as exhibits to the company’s Form 10-K for the year ended December 31, 2025.
Contineum Therapeutics, Inc. completed an underwritten public offering of 7,346,938 shares of its Class A common stock at $12.25 per share. The underwriters purchased the shares at $11.515 per share, and Contineum estimates net proceeds of approximately $84.2 million, assuming no exercise of the underwriters’ option to buy more shares. The company granted the underwriters a 30-day option to purchase up to an additional 1,102,040 shares. The transaction was conducted under an effective Form S-3 shelf registration and closed on December 15, 2025.
Contineum also issued press releases announcing a proposed $75.0 million offering and the pricing of an upsized $90.0 million offering of Class A common stock, highlighting increased deal size as demand solidified.
Contineum Therapeutics, Inc. reported that on December 8, 2025 it submitted details of its global Phase 2 clinical trial of PIPE-791 for idiopathic pulmonary fibrosis to the ClinicalTrials.gov Protocol Registration and Results System, with posting to follow PRS approval.
The 26-week, international, randomized, dose-ranging, double-blind, placebo-controlled study will evaluate once-daily PIPE-791 in about 324 IPF patients, focusing on safety and tolerability and the change from baseline in absolute forced vital capacity at week 26.
The company’s trial design and launch strategy draw on prior regulatory engagement and completed Phase 1 studies, and it expects to begin the trial internationally and add countries as regulatory approvals are obtained, with completion anticipated in June 2028.
Contineum Therapeutics, Inc. (CTNM) reported that it issued a press release with topline data from its Phase 2 PIPE-307 VISTA trial for treating relapsing-remitting multiple sclerosis. The company furnished this press release as Exhibit 99.1 to the report and incorporated it by reference, indicating that detailed clinical results are contained in that exhibit.
Contineum Therapeutics, Inc. furnished an 8-K to announce it issued a press release with financial results for the third quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The information under Item 2.02, including Exhibit 99.1, is being furnished and is not deemed “filed” for purposes of Section 18 of the Exchange Act, and will not be incorporated by reference into any Securities Act registration statement unless specifically identified.
Contineum Therapeutics reported that a pharmacokinetic–pharmacodynamic relationship between exposure to its investigational drug PIPE-791 and LPA1 brain receptor occupancy (RO) was confirmed in both healthy volunteers and progressive multiple sclerosis (PrMS) patients. Plasma EC50 values were 37 ng/mL at 24 hours and 12 ng/mL at 168 hours post-dose, indicating sustained target engagement after dosing. The company states its planned Phase 2 proof-of-concept doses are expected to provide >90% target coverage at trough with once-daily dosing.
The filing also contains customary forward-looking statements and risk disclosures noting that these early clinical results may not predict future outcomes and that development, regulatory, and funding risks could affect plans.
Contineum Therapeutics (Nasdaq: CTNM) filed a routine Form 8-K reporting the voting outcomes of its 2025 virtual Annual Meeting held on June 26, 2025.
Shareholders re-elected Class I directors Sarah Boyce, Troy Ignelzi and Olivia Ware, and ratified Ernst & Young LLP as independent auditor for fiscal 2025. No additional proposals or material events were disclosed.